Partnership Programs

AdvanCell operates a comprehensive partnership program for taking novel Targeted Alpha Therapies from the lab through to Phase I and beyond.

AdvanCell provides its cGMP isotope to partners removing reliance on external supply chains.


AdvanCell’s in-house manufacturing team and infrastructure ensures CMC development to meet FDA requirements.


AdvanCell has deep experience in running clinical trials for radioligand therapies.


Australia’s world-leading Nuclear Medicine expertise and infrastructure offers a smooth and competitive path for clinical development.

Looking to partner for Targeted Alpha Therapy Development?

Get in touch

By sending us a message, you agree to our friendly privacy policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.